08:28 AM EDT, 09/08/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) said Monday that data from three metastatic colorectal cancer, or mCRC studies for its immunotherapy pelareorep showed "consistent efficacy signals, immune activation, and survival outcomes" that exceeded benchmarks in multiple treatment settings.

The REO 022 trial, which evaluates pelareorep in combination with Folfiri and bevacizumab in platinum refractory 2L mCRC KRAS mutant patients, showed median progression-free survival of 16.6 months compared with 5.7 months and median overall survival of 27 months versus 11.2 months with standard 2L regimen1, the clinical-stage company said.

In the Goblet study's third-line cohort, pelareorep with atezolizumab and TAS-102 met its efficacy endpoint, achieving durable disease control and survival above historical benchmarks, the company said.

Data from REO 022 trial and the REO 013 translational study demonstrated viral replication and immune activation in tumors from patients, including dendritic cell maturation and CD8+ T cell activation, the company said.

Oncolytics Chief Executive Jared Kelly said the results show "a clear opportunity" to accelerate the pursuit of a registration-enabled study in "the underserved" KRAS mutant subset of mCRC patients.

Oncolytics said it plans to conduct an investigator-sponsored trial and engage investigators and regulators to establish a roadmap for the registration in mCRC, including the design of a confirmatory study.

Oncolytics shares were up more than 6% in recent Monday premarket activity.